HA35 Moderate Alcoholic Hepatitis (AH) Study

Description

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection. Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.

Conditions

Alcoholic Hepatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection. Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.

Mechanism of HA35 in Patients with Alcoholic Liver Disease

HA35 Moderate Alcoholic Hepatitis (AH) Study

Condition
Alcoholic Hepatitis
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Regular consumption of alcohol with an intake of \>60 g daily or \>420 g weekly on average for men and \>40 g daily or \>280 g weekly on average for women for 6 months or more
  • * MELD \<21
  • * Serum total bilirubin \>3 mg/dL
  • * AST \>50 IU/I; AST:ALT ratio \>1.5; Both AST and ALT \<400 IU/I
  • * Pregnant or breastfeeding women
  • * Patients with gastrointestinal bleeding within 2 weeks
  • * Active infection (positive blood or ascitic fluid culture)
  • * Overt encephalopathy
  • * Renal failure and/or on dialysis
  • * Medications that alter muscle protein metabolism
  • * Myopathies
  • * Other end-stage organ diseases
  • * Malignancy
  • * Solid organ or hematopoietic transplantation
  • * Active alcohol withdrawal or ongoing participation in a Clinical Institute Withdrawal Assessment (CIWA) protocol
  • * History of recent upper gastrointestinal resection within past 6 months
  • * Acute or chronic liver disease due to other active causes, in addition to alcoholic liver disease
  • * Inability to provide consent
  • * Creatinine \>2mg/dL
  • * Platelets \<60,000k/ul
  • * PT/INR \>1.7
  • * Presence of pedal edema
  • * Use of anti-platelet/anticoagulation drugs or medications that interfere with blood clotting

Ages Eligible for Study

21 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Cleveland Clinic,

Study Record Dates

2026-10-01